Profound Med Corp Stock Price, News & Analysis

Profound Medical (NASDAQ:PROF) reported Q2 2025 financial results, with revenue of $2.2 million, unchanged year-over-year, comprising $1.6 million from recurring revenue and $650,000 from capital equipment sales. The company's gross margin improved to 73% from 64% in the prior year.

TULSA-PRO® system showed strong operational metrics with 10% sequential growth in procedure volumes and a pipeline of 80 new systems in various sales stages. The company launched TULSA-AI® Volume Reduction Module for BPH treatment and appointed Leonard Wheeler as Global Ambassador. Despite some delayed capital sales, Profound maintains its guidance of 70-75% year-over-year revenue growth for 2025.

Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. Investors can access the call through registration and listen to the live broadcast on the company's website.

Profound Medical (NASDAQ:PROF) has announced the first commercial BPH treatment using TULSA-PRO® with its new TULSA-AI® Volume Reduction Module. The procedure was performed by Dr. Naveen Kella at The Urology Place. The TULSA-AI® enhancement streamlines treatment planning and reduces procedure time to 60-90 minutes for BPH patients. A recent study from the University of Turku demonstrated TULSA's effectiveness in treating BPH, showing significant improvements in urinary function while preserving sexual function. The treatment offers advantages over traditional methods like TURP, requiring no hospital stay and causing no bleeding. TULSA uses real-time MR guidance and AI-enhanced planning to precisely treat prostate tissue. The company expects this advancement to expand their annual market opportunity from 200,000 to 600,000 prostate disease patients.

Profound Medical Corp (NASDAQ:PROF) has appointed former NFL safety Leonard Wheeler as Global Ambassador for its TULSA-PRO system. Wheeler, who successfully underwent the TULSA procedure for prostate cancer in early 2025, will lead education and awareness initiatives for the company's innovative treatment. The TULSA-PRO system offers an AI-powered, incision-free therapy for prostate conditions, including cancer and BPH, using real-time MR guidance and sound absorption technology. Wheeler, a nine-year NFL veteran turned executive coach and entrepreneur, brings extensive experience in leadership and public speaking through his company Trilucent Global. His personal experience with TULSA-PRO and successful treatment at The Busch Center positions him uniquely to advocate for this alternative to traditional prostate treatments. The partnership aims to expand awareness and adoption of TULSA-PRO among physicians, patients, and private payers through various media channels.

Profound Medical Corp (NASDAQ: PROF) held its Annual General and Special Meeting with strong shareholder participation, as 68.5% of outstanding shares (20,587,011 shares) were represented. All six director nominees were successfully elected to the Board with approval rates ranging from 92.4% to 97%. The highest approval was received by Cynthia Lavoie (97%), while Arthur Rosenthal received the lowest support (92.4%). Shareholders also approved the appointment of PricewaterhouseCoopers LLP as the company's auditor and passed a resolution approving unallocated options under the company's share option plan.

Profound Medical (NASDAQ: PROF) reported strong Q1 2025 financial results, with revenue growing 82% to $2.6 million compared to Q1 2024. The revenue comprised $1.8 million from recurring non-capital revenue and $820,000 from capital equipment sales. Gross margin improved to 71% from 60% year-over-year. The company's TULSA-PRO® treatment data showed diverse patient applications: 82% for prostate cancer, 10% hybrid cases, and 8% salvage cases. However, operating expenses increased to $13.0 million from $8.7 million, leading to a net loss of $10.7 million ($0.36 per share). The company maintained a strong cash position of $46.4 million as of March 31, 2025. Notable developments include positive initial results from the CAPTAIN trial comparing TULSA to robotic radical prostatectomy and new Urology APC Level 7 codes effective 2025.

Profound Medical (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company, announced its upcoming participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The company, which specializes in developing customizable, incision-free therapies for diseased tissue ablation, will present a business update on Tuesday, May 6, 2025, at 1:30 p.m. Eastern Time.

The presentation will take place at the Metro Toronto Convention Centre. Investors and interested parties can access the live broadcast and archived recording through the "Webcasts" section under Investors on the company's website at www.profoundmedical.com.

Profound Medical has announced groundbreaking results from their CAPTAIN trial, comparing TULSA procedure with robotic radical prostatectomy (RP) for prostate cancer treatment. The Level 1 study, involving 201 randomized patients across 23 sites, demonstrates significant advantages for TULSA.

Key findings show TULSA patients experienced:

• Zero blood loss compared to 100-200mL for RP
• 0.29 days hospital stay versus 1.24 days for RP
• Significantly lower post-operative pain through day 6
• Higher overall health scores for 30 days post-treatment

TULSA patients showed notably better outcomes in mobility (0% vs 12% extreme problems), self-care (3% vs 17%), and usual activities (17% vs 40%). The study included balanced patient characteristics, with median age ~63 years and similar PSA levels between groups. These results position TULSA as a potentially superior alternative to traditional prostate cancer surgery.

Profound Medical (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company focused on developing incision-free ablation therapies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments from the period. Investors can access the live call through registration and the broadcast will be archived on the company's website under the Investors section.